Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1

Conditions

Melanoma 2Sarcoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × IMM-101 × Clear all
NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
2 enrolled 7 charts
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT01559818 2023-06-22

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
10 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡